	US 11,684,677 B2
	Compositions
Scott Crowe, Cambridge (GB); Kevin Roberts, Cambridge (GB); Tim Carlton, Cambridge (GB); Luana Maggiore, Cambridge (GB); Marion Cubitt, Cambridge (GB); Mike West, Cambridge (GB); and Keith Ray, Cambridge (GB)
Assigned to SORRISO PHARMACEUTICALS, INC., San Diego, CA (US)
Filed by Sorriso Pharmaceuticals, Inc., San Diego, CA (US)
Filed on Mar. 27, 2019, as Appl. No. 16/366,454.
Application 16/366,454 is a continuation in part of application No. PCT/EP2017/074828, filed on Sep. 29, 2017.
Claims priority of application No. 16191988 (EP), filed on Sep. 30, 2016.
Prior Publication US 2019/0307891 A1, Oct. 10, 2019
Int. Cl. A61P 1/00 (2006.01); A61K 9/00 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 47/68 (2017.01); A61K 47/65 (2017.01)

CPC A61K 47/6849 (2017.08) [A61K 9/0053 (2013.01); A61K 47/65 (2017.08); A61K 47/6845 (2017.08); A61P 1/00 (2018.01); C07K 16/241 (2013.01); C07K 16/2866 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/542 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

14 Claims

1. A composition comprising:

(a) an TNF-alpha-binding VHH, said TNF-alpha-binding VHH comprising three complementarity determining regions (CDR1-CDR3), wherein CDR1 comprises SEQ ID NO: 1, CDR2 comprises SEQ ID NO: 2 and CDR3 comprises SEQ ID NO: 3; and

(b) an IL-6R-binding VHH, said IL-6R-binding VHH comprising three complementarity determining regions (CDR1-CDR3), wherein CDR1 comprises SEQ ID NO: 9, CDR2 comprises SEQ ID NO: 10 and CDR3 comprises SEQ ID NO: 11.